Skip to content
10-Q

Quarterly Report

REGEN BIOPHARMA, INC. RGBP RGBPP

0001493152-26-006526

← back to feed
Filed
Feb 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Feb 2, 2026 129.47M sh
Shares Diluted Q1 2026 · Dec 31, 2025 99.61M sh
Shares Diluted Q1 2026 · Dec 31, 2024 4.11M sh
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$197.94K
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$66.38K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.58K
Cash And Equivalents Q1 2026 · Sep 30, 2025 $69.56K
Stockholders Equity Q1 2026 · Dec 31, 2025 −$6.57M
Stockholders Equity Q1 2026 · Sep 30, 2025 −$6.28M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$5.68M
Stockholders Equity Q1 2026 · Sep 30, 2024 −$5.22M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.81M
Current Liabilities Q1 2026 · Sep 30, 2025 $6.56M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.81M
Total Liabilities Q1 2026 · Sep 30, 2025 $6.56M
Current Assets Q1 2026 · Dec 31, 2025 $237.08K
Current Assets Q1 2026 · Sep 30, 2025 $274.63K
Total Assets Q1 2026 · Dec 31, 2025 $237.08K
Total Assets Q1 2026 · Sep 30, 2025 $274.63K
Eps Diluted Q1 2026 · Dec 31, 2025 −$0.01
Eps Diluted Q1 2026 · Dec 31, 2024 −$0.13
Eps Basic Q1 2026 · Dec 31, 2025 −$0.01
Eps Basic Q1 2026 · Dec 31, 2024 −$0.13
Rd Expense Q1 2026 · Dec 31, 2025 $210K
Rd Expense Q1 2026 · Dec 31, 2024 $0
Net Income Q1 2026 · Dec 31, 2025 −$967.85K
Net Income restated Q1 2026 · Dec 31, 2024 −$515.38K
Operating Income Q1 2026 · Dec 31, 2025 −$551.62K
Operating Income Q1 2026 · Dec 31, 2024 −$61.38K
Revenue Q1 2026 · Dec 31, 2025 $59.07K
Revenue Q1 2026 · Dec 31, 2024 $59.07K